Other well-established and relevant GPCRs linked to autoimmunity and MS are the sphingosine-1-phosphate receptors [45,46], which are specifically targeted by the best available drugs approved for the treatment of relapsing and secondary progressive MS forms, such as fingolimod [47] and siponimod [48]. This evidence concerns the gene S1PR1 and myeloid sarcoma.